Revenue distribution by sectors:

• Vaccines: 70%
• Biopharmaceuticals: 20%
• Diagnostics: 10%

TOP 3 markets and their percentage shares:

• China: 60%
• Southeast Asia: 20%
• Latin America: 15%

Walvax Biotechnology Co., Ltd. generates the majority of its revenue from the vaccine sector, which is due to the growing demand for vaccines against various diseases. The Chinese market is the largest single market for the company, followed by Southeast Asia and Latin America, which also make significant contributions. These markets benefit from increasing healthcare services and government vaccination programs.

Production Sites: China (Main Production Facilities)

Walvax Biotechnology Co., Ltd. is a leading biotechnology company in China specializing in the research, development, and production of vaccines. The company's main production facilities are located in China, where it utilizes state-of-the-art technologies and facilities to produce high-quality vaccines.

In recent years, the company has expanded its production capacities to meet the increasing demand for vaccines both domestically and internationally. Walvax continuously invests in the modernization and expansion of its production plants to comply with global standards and enhance its competitiveness.

Focus on mRNA Technology: Walvax Biotechnology has heavily invested in the development of mRNA vaccines in recent years.

International Expansion: The company plans to expand its presence in international markets, especially in emerging countries.

Research and Development: Increasing R&D spending to develop innovative biopharmaceutical products.

Walvax Biotechnology Co., Ltd. is banking on mRNA technology as a central pillar for future growth. By developing and commercializing mRNA vaccines, the company aims to take a leading position in the global vaccine market.

In addition, Walvax is pursuing a strategy of international expansion to establish its products in new markets. This includes both building partnerships and directly launching products in various countries.

Another key aspect of the growth strategy is the increased investment in research and development. By boosting R&D budgets, the company aims to enhance its innovation capabilities and bring new biopharmaceutical products to the market.

Main raw materials: Biotechnological reagents, vaccine components, pharmaceutical active ingredients

Main importing countries: USA, Germany, India

Walvax Biotechnology Co., Ltd. imports a variety of raw materials essential for the production of vaccines and biotechnological products. These include biotechnological reagents and pharmaceutical active ingredients. The USA and Germany are leading suppliers of high-quality biotechnological reagents, while India often supplies pharmaceutical active ingredients.

These imports are crucial for the production efficiency and the quality of Walvax's end products. The selection of importing countries is based on the availability of specialized materials and the quality of the supplied raw materials.

Market share in China: 25% (estimated for 2026)
Research and development budget: 15% of revenue (2025)
Product diversification: 10 vaccines in the portfolio (2026)

Walvax Biotechnology Co., Ltd. has a significant competitive advantage in the Chinese biotechnology market, especially in the field of vaccines. The company holds an estimated market share of 25% in China, making it one of the leading providers in this sector.

A key factor for this advantage is the high commitment to research and development, accounting for about 15% of revenue. This enables Walvax to continuously develop and bring innovative products to the market.

Furthermore, the company has a diversified product portfolio with 10 different vaccines, further strengthening its market position and reducing the risk of revenue fluctuations due to dependence on a single product. These strategic measures help to secure and expand Walvax's competitive advantage in the biotechnology sector.

Institutional Investor Share: Estimated at 35% (2026)
Insider Buys/Sells: No significant transactions in the last 12 months (2026)

The institutional investor share in Walvax Biotechnology Co., Ltd. is estimated to be around 35%. This reflects the interest of institutional investors who have confidence in the company's growth potential.

Regarding insider transactions, there have been no significant buys or sells in the past year, which could indicate a stable assessment of the company's value by management and other insiders. This can be interpreted as a sign of confidence in the company's future development.

Market share of Walvax Biotechnology Co., Ltd.: 8% (2026, estimated)

Top competitors and their market shares:

1. Sinovac Biotech Ltd.: 15%
2. CanSino Biologics Inc.: 12%
3. Zhifei Biological Products Co., Ltd.: 10%
4. Walvax Biotechnology Co., Ltd.: 8%
5. Chongqing Zhifei Biological Products Co., Ltd.: 7%
6. Shenzhen Kangtai Biological Products Co., Ltd.: 6%
7. Hualan Biological Engineering Inc.: 5%
8. Beijing Tiantan Biological Products Co., Ltd.: 4%
9. Shanghai Fosun Pharmaceutical Group Co., Ltd.: 3%
10. Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.: 2%

Moat of Walvax Biotechnology Co., Ltd.:

Walvax Biotechnology Co., Ltd. has established a certain moat through its innovation and development of vaccines, especially in the field of mRNA technology. The strategic partnership with international pharmaceutical companies has strengthened its research and development capabilities.

However, companies like Sinovac and CanSino have a stronger moat due to their established production capacities and global presence. Sinovac benefits from a wide product portfolio and a strong international market presence, while CanSino stands out for its rapid development cycles and the ability to respond to new health threats.

Overall, Walvax has a significant advantage in innovation, but they need to further expand their production capacities and international expansion to keep up with the leading companies.

Revenue Growth: 18% (estimated for 2026)
Research and Development Expenses: 20% of revenue (2025)
Market Share in the Vaccine Sector: 12% (2025)

Walvax Biotechnology Co., Ltd. has experienced strong revenue growth in recent years, estimated at around 18% for 2026. This is an indicator of the increasing demand for their products and successful expansion into new markets.

The company is investing significantly in research and development, with expenses accounting for approximately 20% of revenue. These investments suggest that Walvax is striving to expand its product pipeline and develop innovative solutions in the biotechnology field.

With a 12% market share in the vaccine sector, Walvax demonstrates a strong market presence. This is particularly relevant in a growing global health market driven by demand for vaccines and biotechnological innovations.

Overall, these factors indicate that Walvax Biotechnology Co., Ltd. represents a promising investment opportunity, especially for investors interested in long-term growth in the biotechnology sector.

Dividend payment: No current data available (2026)

Walvax Biotechnology Co., Ltd. has not made regular dividend payments to its shareholders in the past. The company is primarily engaged in biopharmaceutical research and development, which is often associated with high investments in research and development.

Companies in this industry tend to reinvest profits into growth and the development of new products rather than paying out dividends. Therefore, it is unlikely that Walvax will pay a dividend in the near future unless there are significant changes in the company's strategy or financial status.